Comparative Pharmacology
Head-to-head clinical analysis: PEMETREXED versus PEMETREXED FOR INJECTION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEMETREXED versus PEMETREXED FOR INJECTION.
PEMETREXED vs PEMETREXED FOR INJECTION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), leading to inhibition of de novo purine and pyrimidine synthesis.
Pemetrexed is a folate analog metabolic inhibitor that inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), enzymes involved in folate-dependent de novo synthesis of thymidine and purine nucleotides, thereby disrupting DNA and RNA synthesis.
500 mg/m2 IV over 10 minutes on Day 1 of each 21-day cycle, with folic acid and vitamin B12 supplementation.
500 mg/m² IV over 10 minutes on Day 1 of each 21-day cycle, in combination with cisplatin 75 mg/m² IV over 2 hours starting 30 minutes after pemetrexed completion. Administer folic acid 350-1000 µg po daily starting 7 days before first dose and continuing until 21 days after last dose, vitamin B12 1000 µg IM 7 days before first dose and every 3 cycles thereafter, and dexamethasone 4 mg po twice daily on day before, day of, and day after pemetrexed.
None Documented
Clinical Note
moderatePemetrexed + Digoxin
"Pemetrexed may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePemetrexed + Digitoxin
"Pemetrexed may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePemetrexed + Deslanoside
"Pemetrexed may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePemetrexed + Acetyldigitoxin
"Pemetrexed may decrease the cardiotoxic activities of Acetyldigitoxin."
None Documented
Terminal half-life is approximately 3.5 hours in patients with normal renal function (creatinine clearance ≥60 mL/min). Clinically, half-life is prolonged in renal impairment (up to 20 hours in severe impairment), requiring dose adjustment.
The terminal elimination half-life is approximately 3-4 hours in patients with normal renal function (creatinine clearance ≥90 mL/min). In patients with impaired renal function (creatinine clearance 45-79 mL/min), the half-life may be prolonged to 4-5 hours.
Primarily eliminated unchanged in urine (70-90% of dose via renal excretion over 24 hours); minimal biliary/fecal excretion (<5%).
Approximately 70-90% of the administered dose is excreted unchanged in the urine within 24 hours. Renal elimination is the primary route, with negligible biliary or fecal excretion (<5%).
Category C
Category C
Antineoplastic Antifolate
Antineoplastic Antifolate